The inhibition of miR-122 protects hepatocytes from lipid metabolic disorders such as NAFLD and suppresses lipogenesis via elevating Sirt1 and activating the AMPK pathway. This evidence concerns the gene SIRT1 and metabolic dysfunction-associated steatotic liver disease.